Skip to main content
. 2022 Aug 2;12:837963. doi: 10.3389/fonc.2022.837963

Table 4.

Response and survival data (FAS population).

HX008+GP
response n (%)
Complete response 1 (3.2%)
Partial response 24 (77.4%)
Stable disease 6 (19.4%)
Progressive disease 0
Missing data or not assessable 0
Overall response 80.6% (62.53%–92.55%)
Progression-free survival
Number of events 26
Median progression-free survival, months(95% CI) 9.00 (6.18–9.20)
Overall survival
Number of events 10
Median overall survival, months (95% CI) NE (15.54, NE)